SEC Filing Summary: Harvard Bioscience, Inc. (HBIO)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Harvard Bioscience, Inc. on August 11, 2026. The filing serves as a Regulation FD disclosure to distribute a corporate slide presentation to the investment community, providing updates and summaries of the company's business.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a conduit for a presentation (Exhibit 99.1) rather than containing the financial data itself.
Material Changes
No material changes to financial performance or operations are detailed within the text of this filing. The report solely announces the availability of the corporate presentation.
Guidance, Outlook, and Risks
Management commentary, guidance, and risk factors are contained within the attached corporate slide presentation (Exhibit 99.1). The filing explicitly states that the information in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section, nor is it incorporated by reference in other filings except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Corporate Slide Presentation) for actual financial data, guidance, and strategic updates.
- Verify the date of the presentation to ensure it aligns with the August 2026 reporting period.
- Note that the presentation content is not legally "filed" under Section 18 of the Exchange Act, which may affect liability standards for the information provided.
- Confirm the trading symbol (HBIO) and exchange (NASDAQ Capital Market) for current market data.